Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
4 participants
INTERVENTIONAL
2014-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Saline
Saline administered IV for 12 hours
Saline
Lower Dose
MST-188 loading dose 100 mg/kg IV for 1 hour followed by 25 mg/kg/hr for 11 hours
MST-188
Higher Dose
MST-188 loading dose 200 mg/kg IV for 1 hour followed by 75 mg/kg/hr for 11 hours
MST-188
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MST-188
Saline
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Symptoms consistent with ALI in target lower limb classified as Rutherford Category IIa or IIb
* Subject is hospitalized or in the process of hospitalization for the treatment of ALI
* Angiographic confirmation of thrombotic lower limb arterial occlusion
Exclusion Criteria
* Treatment with a thrombolytic agent within the last 48 hours
* Subject's laboratory results indicate inadequate organ function
* NYHA Class IV congestive heart failure
* Prior major amputation of the target limb
* Other complications or contraindications for receiving rt-PA, anticoagulants, or contrast media
30 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mast Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Edwin L Parsley, D.O.
Role: STUDY_DIRECTOR
Mast Therapeutics, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Center
Little Rock, Arkansas, United States
Research Center
Tampa, Florida, United States
Research Center
Brooklyn, New York, United States
Research Center
Cleveland, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MST-188-07
Identifier Type: -
Identifier Source: org_study_id